Loading...
Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma
Edeline, J. Lamarca, Angela McNamara, Mairead G Jacobs, Timothy Hubner, Richard A Palmer, D. Johnson, P. Guiu, B Valle, Juan W
Edeline, J.
Lamarca, Angela
McNamara, Mairead G
Jacobs, Timothy
Hubner, Richard A
Palmer, D.
Johnson, P.
Guiu, B
Valle, Juan W
Citations
Altmetric:
Abstract
Background:Locoregional treatments (LRT) including radioembolisation (SIRT),transarterial chemo-embolisation (TACE), hepatic arterial infusion (HAI) of chemo-therapy, external beam radiotherapy (EBRT) and ablation, have been studied for themanagement of intrahepatic cholangiocarcinoma (iCC). The aim of this systematicreview was to provide outcome benchmarks for clinical trial design.Methods:Identification of studies reporting outcomes of patients treated with LRTfor iCC was performed using PubMed and Embase. Pooled weighted means werecalculated for progression-free survival (PFS) and overall survival (OS); meta-analysisof proportions was used for estimation of pooled response rate.Results:6325 entries were reviewed; 93 studies were eligible, representing 101 co-horts and a total of 3990 patients [15 cohorts (645 patients) for ablation, 18 cohorts(541 patients) for EBRT, 27 cohorts (1232 patients) for SIRT, 22 cohorts (1145 patients)for TACE, 16 cohorts (331 patients) for HAI and 3 cohorts (96 patients) not pooled].74% of the studies were retrospective, 93% non-randomised; and 19% were onlyavailable in abstract form. The pooled mean weighted OS was 30.2 months (95%confidence interval (CI): 21.8-38.6) for ablation, 18.9 (14.2-23.5) for EBRT, 14.1 (12.1-16.0) for SIRT, 15.9 (12.9-19.0) for TACE and 21.3 (15.4-27.1) for HAI. The pooledcomplete response rate was 93.9% for ablation. When analysed together, SIRT, TACEand HAI had a pooled mean weighted OS of 15.7 months (all patients) and 25.2months for patients treated infirst-line with concomitant systemic chemotherapy.Conclusions:Available literature on LRT for iCC was heterogeneous and of insufficientquality to make strong recommendations. Ablation achieved satisfactory outcomes,and may be recommended when surgery is not feasible. Benchmark outcome esti-mates are provided to inform the design of phase III trials.
Affiliation
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 83.07 KB
Keywords
Type
Meetings and Proceedings
Citation
Edeline J, Lamarca A, McNamara M, Jacobs T, Hubner R, Palmer D, et al. P-229 Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma. Annals of Oncology. 2021 Jul;32:S177.